Abstract
Adjuvant therapy for completely resected esophageal squamous cell carcinoma is less commonly applied in clinical practice than neoadjuvant therapy, but it plays a substantial role in improving survival for esophageal cancer patients. This article presents a concise review of the evidence regarding adjuvant therapy for esophageal squamous cell carcinoma and future directions, particularly immunotherapy.
| Original language | English |
|---|---|
| Pages (from-to) | 168-171 |
| Number of pages | 4 |
| Journal | Korean Journal of Thoracic and Cardiovascular Surgery |
| Volume | 53 |
| Issue number | 4 |
| DOIs | |
| State | Published - 1 Aug 2020 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Adjuvant therapy
- Esophageal neoplasms
- Immunotherapy
- Neoadjuvant therapy
Fingerprint
Dive into the research topics of 'Adjuvant therapy for esophageal squamous cell carcinoma'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver